Randomized phase II study of sunitinib versus standard of care forpatients with previously treated advanced triple-negative breastcancer

Breast

Volumn 22, Issue 5, 2013, Pages 650-656

  Curigliano, Giuseppe ^a   Pivot, Xavier ^b   Cortés, Javer ^c   Elias, Anthony ^d   Cesari, Rossano ^e   Khosravan, Reza ^e   Collier, Mary ^e   Huang, Xin ^e   Cataruozolo, Patricia E ^e   Kern, Kenneth A ^e   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF COLORADO   (United States)

^e PFIZER INC   (United States)

Author keywords

Phase II; Receptor tyrosine kinases; Standard of care chemotherapy; Sunitinib; Triple negative breast cancer

Indexed keywords

CAPECITABINE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERYTHEMA; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISCOLORATION; STANDARD; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

ADVERSE EVENTS; AES; AND COLONY-STIMULATING FACTOR-1 RECEPTOR; BC; BREAST CANCER; CDD; CI; COMPUTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTINUOUS DAILY DOSING; CSF-1R; CT; ER; HER2; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; KIT; MRI; NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; NCI CTCAE V3.0; OBJECTIVE RESPONSE RATE; OR MAGNETIC RESONANCE IMAGING; ORR; OS; OVERALL SURVIVAL; PDGFR; PFS; PHASE II; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; PROGRESSION-FREE SURVIVAL; RDI; RECEPTOR TYROSINE KINASES; RECIST; RELATIVE DOSE INTENSITY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SOC; SPIRAL CT; STANDARD-OF-CARE; STANDARD-OF-CARE CHEMOTHERAPY; STEM-CELL FACTOR RECEPTOR; SUNITINIB; THE ESTROGEN RECEPTOR; TNBC; TRIPLE-NEGATIVE BREAST CANCER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR; VERSION 3.0;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; PYRROLES; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884151634     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.037     Document Type: Article

References (29)

1. Elias A.D. Triple-negative breast cancer. Am J Clin Oncol 2010, 33:637-645.
2. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
3. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007, 109:1721-1728.
4. Banerjee S., Dowsett M., Ashworth A., Martin L.A. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007, 4:536-550.
5. Paulsson J., Sjöblom T., Micke P., Pontén F., Landberg G., Heldin C.H., et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175:334-341.
6. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005, 65:5278-5283.
7. Charpin C., Giusiano S., Charfi S., Secq V., Carpentier S., Andrac L., et al. Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome. Br J Cancer 2009, 101:48-54.
8. Tsuda H., Tani Y., Weisenberger J., Kitada S., Hasegawa T., Murata T., et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Sci 2005, 96:333-339.
9. Herr A., Gluz O., Ting E., Mohrmann S., Werner F., Schuett G. Biological characteristics in triple negative high risk breast cancer and their clinical implications [abstract]. JClin Oncol 2006, 24(Suppl.18s):20032.
10. Thike A.A., Cheok P.Y., Jara-Lazaro A.R., Tan B., Tan P., Tan P.H. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010, 23:123-133.
11. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
12. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
13. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. Invivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
14. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:757-766.
15. Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. JClin Oncol 2008, 26:1810-1816.
16. Escudier B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S.F., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. JClin Oncol 2009, 27:4068-4075.
17. Barrios C.H., Hernandez-Barajas D., Brown M.P., Lee S.H., Fein L., Liu J.H., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1252-1259.
18. George S., Blay J.Y., Casali P.G., Le Cesne A., Stephenson P., Deprimo S.E., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45:1959-1968.
19. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEngl J Med 2011, 364:501-513.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNatl Cancer Inst 2000, 92:205-216.
21. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
22. Corless C.L., Heinrich M.C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008, 3:557-586.
23. Simon R., Panussis S., Maurer R., Spichtin H., Glatz K., Tapia C., et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004, 10:178-183.
24. Barrios C.H., Liu M.C., Lee S.C., Vanlemmens L., Ferrero J.M., Tabei T., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
25. Robert N.J., Saleh M.N., Paul D., Generali D., Gressot L., Copur M.S., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011, 11:82-92.
26. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. JClin Oncol 2012, 30:921-929.
27. Crown J.P., Diéras V., Staroslawska E., Yardley D.A., Bachelot T., Davidson N., et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013 Jul 15, [Epub ahead of print].
28. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009, 15:220-231.
29. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15:232-239.